Genmab A/S (NASDAQ:GMAB) Receives $45.20 Consensus Target Price from Brokerages

Genmab A/S (NASDAQ:GMAB) has earned an average recommendation of “Hold” from the thirteen ratings firms that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $45.20.

GMAB has been the subject of several analyst reports. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Friday. BTIG Research increased their price objective on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Truist Financial lowered their target price on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a report on Monday, September 9th. Royal Bank of Canada raised shares of Genmab A/S from a “sector perform” rating to an “outperform” rating in a research note on Monday, July 15th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Genmab A/S in a research note on Tuesday, August 20th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Capital International Investors grew its stake in shares of Genmab A/S by 7.8% in the first quarter. Capital International Investors now owns 4,373,277 shares of the company’s stock valued at $130,805,000 after buying an additional 315,355 shares in the last quarter. Harding Loevner LP boosted its holdings in Genmab A/S by 2.7% in the 4th quarter. Harding Loevner LP now owns 3,289,895 shares of the company’s stock worth $97,569,000 after acquiring an additional 85,665 shares during the period. Renaissance Technologies LLC grew its position in Genmab A/S by 7.6% in the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock valued at $36,752,000 after acquiring an additional 103,859 shares in the last quarter. First Trust Advisors LP grew its position in Genmab A/S by 16.0% in the fourth quarter. First Trust Advisors LP now owns 1,270,095 shares of the company’s stock valued at $40,440,000 after acquiring an additional 175,292 shares in the last quarter. Finally, DDD Partners LLC purchased a new stake in shares of Genmab A/S during the second quarter valued at approximately $8,860,000. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Price Performance

Genmab A/S stock opened at $26.90 on Wednesday. The firm’s 50-day moving average is $27.25 and its two-hundred day moving average is $28.07. The stock has a market capitalization of $17.79 billion, a P/E ratio of 22.42, a P/E/G ratio of 0.81 and a beta of 0.99. Genmab A/S has a 12-month low of $24.53 and a 12-month high of $38.80.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.07). The firm had revenue of $779.50 million for the quarter, compared to analyst estimates of $734.60 million. Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. As a group, analysts forecast that Genmab A/S will post 1.27 EPS for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.